Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Bacillus anthracis | Anthrax lethal factor | Starlite/ChEMBL | References |
Homo sapiens | cathepsin B | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Plasmodium falciparum | dipeptidyl aminopeptidase 1 | cathepsin B | 339 aa | 368 aa | 26.9 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | cathepsin B-like peptidase (C01 family) | 0.0166 | 0.5 | 0.5 |
Echinococcus granulosus | cathepsin b | 0.0166 | 0.5 | 0.5 |
Echinococcus granulosus | cathepsin b | 0.0166 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0166 | 0.5 | 0.5 |
Schistosoma mansoni | cathepsin B-like peptidase (C01 family) | 0.0166 | 0.5 | 0.5 |
Schistosoma mansoni | SmCB2 peptidase (C01 family) | 0.0166 | 0.5 | 0.5 |
Schistosoma mansoni | cathepsin B-like peptidase (C01 family) | 0.0166 | 0.5 | 0.5 |
Echinococcus multilocularis | cathepsin b | 0.0166 | 0.5 | 0.5 |
Echinococcus multilocularis | cathepsin b | 0.0166 | 0.5 | 0.5 |
Trypanosoma cruzi | cysteine peptidase C (CPC), putative | 0.0166 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (binding) | Inhibition of porcine aminopeptidase M at 155 uM | ChEMBL. | 16913712 | |
Activity (binding) | Inhibition of human chymotrypsin at 155 uM | ChEMBL. | 16913712 | |
Activity (binding) | Inhibition of human MMP9 at 155 uM | ChEMBL. | 16913712 | |
Activity (binding) | 0 | Inhibition of human MMP9 at 155 uM | ChEMBL. | 16913712 |
Activity (binding) | 0 | Inhibition of human chymotrypsin at 155 uM | ChEMBL. | 16913712 |
Activity (binding) | 0 | Inhibition of porcine aminopeptidase M at 155 uM | ChEMBL. | 16913712 |
CC50 (ADMET) | = 203.84 uM | Cytotoxicity against human MT2 cells after 4 days by XTT assay | ChEMBL. | 19053778 |
IC50 (binding) | = 7.6 uM | Inhibition of Anthrax lethal factor activity by microplate assay | ChEMBL. | 16913712 |
IC50 (binding) | = 7.6 uM | Inhibition of Anthrax lethal factor activity by microplate assay | ChEMBL. | 16913712 |
IC50 (binding) | = 10.1 uM | Inhibition of human cathepsin B | ChEMBL. | 16913712 |
IC50 (binding) | = 10.1 uM | Inhibition of human cathepsin B | ChEMBL. | 16913712 |
IC50 (binding) | = 60.5 uM | Inhibition of human plasma kallikrein | ChEMBL. | 16913712 |
IC50 (binding) | = 60.5 uM | Inhibition of human plasma kallikrein | ChEMBL. | 16913712 |
IC50 (binding) | = 124.9 uM | Inhibition of human neutrohil elastase | ChEMBL. | 16913712 |
IC50 (binding) | = 124.9 uM | Inhibition of human neutrohil elastase | ChEMBL. | 16913712 |
Ki (binding) | = 0.9 uM | Binding affinity to Anthrax lethal factor | ChEMBL. | 16913712 |
Ki (binding) | = 0.9 uM | Binding affinity to Anthrax lethal factor | ChEMBL. | 16913712 |
Ki (binding) | = 10.9 uM | Binding affinity to Anthrax lethal factor-substrate complex | ChEMBL. | 16913712 |
Ki (binding) | = 10.9 uM | Binding affinity to Anthrax lethal factor-substrate complex | ChEMBL. | 16913712 |
Log EC50 (binding) | = 5.68 | Inhibition of HIV1 gp41 | ChEMBL. | 18226912 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
2 literature references were collected for this gene.